study of interest: for relapse b-cell lymphoma after allo SCT

[Guest guest]

Administration of Anti-CD19-Chimeric-Antigen-Receptor-Transduced T Cells

From the Original Transplant Donor to Patients With Recurrent or Persistent

B-Cell Malignancies After Allogeneic Stem Cell Transplantation

NCI-10-C-0054

Link to study details: http://bit.ly/gUw3gV

Study Outline:

• The alloHSCT recipient will receive the donor’s** engineered anti-CD19 T

cells as an intravenous (IV) infusion

• Recipients will be monitored for 72 hours after cell infusion as

inpatients

 

• Visits to the clinic 1, 2, 3, 4, 8, and 12 weeks after the infusion,

followed by visits every 3 months, and then every 6 months, and then yearly

for a minimum of 5 years

Notes:

• This trial will be conducted at the NIH Clinical Center in Bethesda, MD.

It is open to patients who meet the eligibility requirements, regardless of

where they live in the United States.

• There is no charge for medical care received at NIH Clinical Center.

All the best,

~ Karl

Patients Against Lymphoma

Patients Helping Patients

Non-profit | Independent | Evidence-based

www.lymphomation.org | Current News: http://bit.ly/f2A0T

How to Help: www.lymphomation.org/how-to-help.htm